Mast Therapeutics (MSTX) has risen sharply, recording gains of 1.03% in the past 4 weeks. However, the stock has corrected -11.69% in the past 1 week, providing a good buying opportunity on dips. Mast Therapeutics (MSTX) : During the past 4 weeks, traders have been relatively bearish on Mast Therapeutics (MSTX), hence the stock is down -3.2% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -12.99% relative to the S&P 500. The stock has recorded a 20-day Moving Average of 4.88% and the 50-Day Moving Average is 10.56%.
Mast Therapeutics (NYSEMKT:MSTX): The stock opened at $0.45 on Friday but the bulls could not build on the opening and the stock topped out at $0.45 for the day. The stock traded down to $0.43 during the day, due to lack of any buying support eventually closed down at $0.43 with a loss of -1.79% for the day. The stock had closed at $0.44 on the previous day. The total traded volume was 2,613,851 shares.
The company Insiders own 4.26% of Mast Therapeutics shares according to the proxy statements. Institutional Investors own 13.92% of Mast Therapeutics shares. In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the CFO of Mast Therapeutics, Inc., Roberts Brandi, had purchased 38,000 shares in a transaction dated on March 26, 2015. The transaction was executed at $0.5 per share with total amount equaling $19,000.
Mast Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops therapies for serious or life-threatening diseases with unmet needs. The Company leverages its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, the Companys lead product candidate. Vepoloxamer is being tested in a Phase III clinical study called EPIC for the treatment of vaso-occlusive crisis in patients with sickle cell disease. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. AIR001 is being tested in multiple institution-sponsored Phase IIa clinical studies that provide the Company with data on AIR001s potential to treat patients with preserved ejection fraction (HFpEF).